Enterococcal Pathogenesis:Role of Cytolysin

肠球菌发病机制:溶细胞素的作用

基本信息

  • 批准号:
    9322594
  • 负责人:
  • 金额:
    $ 41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-09-23 至 2020-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Enterococci have emerged as leading causes of multidrug resistant hospital infection. Yet they have existed as commensal microbes of everything from insects to man for over 400 million years. Our previous work, as well as the work of others, has shown that one of the factors that makes hospital isolate of Enterococcus faecalis more virulent is a toxin termed "cytolysin." The E. faecalis cytolysin has antibacterial properties, as well as being a cytolytic toxin for human cells. We previously showed that this toxin contributed a 5-fold increased risk of death from infection, that it was conveyed on a pathogenicity island along with several additional virulence traits, and that its expression is regulated by a novel process termed "telesensing" that allows the bacterium to detect the presence of target cells in the vicinity, and in respose produce high levels of the toxin. Although we have shown that the E. faecalis cytolysin toxi is novel in structure and regulation, we do not yet know how it contributes to the severity of infection in man, or in models of infection where it renders E. faecalis infection as much as 100 times more acutely toxic. We also do not know exactly how "telesensing" works at the level of transcription. Therefore, we propose to determine whether the antibacterial property of the toxin allows E. faecalis entry into the GI tract microbiota, whether it there causes changes in the bacterial composition and overgrows within the colon because of the antibacterial activity, whether it compromises the barrier function of the colon through its cytolytic activity for mammalian cells, or whether it exacerbates infection by impeding the innate immune system from clearing the organism from a site of infection. To understand how its expression is regulated, we also propose to dissect the novel two component regulatory system which has been shown to be necessary for its repression and depression. This will be done by mapping the precise points where transcription of the cytolysin operon is initiated, and determining the relationship between those start sites and structural features of the regulatory region of the operon. We will determine whether the inducing signal that results in high level toxin expression is communicated from the outside of the cell, or whether t is internalized and directly causes operon depression. Finally, we will determine exactl how each of the regulatory proteins relate to each other, and relate to structural features within the control region of the cytolysin operon. These results will provide needed information for knowing how the cytolysin exacerbates E. faecalis infection, as well as the information needed for controlling its expression.
描述(由申请人提供):肠球菌已成为多重耐药医院感染的主要原因。然而,它们作为从昆虫到人类的各种生物的共生微生物已经存在了4亿多年。我们之前的工作以及其他人的工作已经表明,使医院分离的粪肠球菌毒性更强的因素之一是一种称为“溶细胞素”的毒素。粪肠杆菌溶细胞素具有抗菌作用,同时也是人体细胞的溶细胞毒素。我们之前的研究表明,这种毒素导致感染死亡的风险增加了5倍,它是在一个致病性岛上传播的,同时还有几个额外的毒力特征,它的表达受一种被称为“远程传感”的新过程的调节,这种过程允许细菌检测到附近目标细胞的存在,并作为反应产生高水平的毒素。虽然我们已经证明粪肠杆菌溶细胞素毒素在结构和调控上是新颖的,但我们还不知道它是如何导致人类感染的严重程度的,或者在感染模型中它使粪肠杆菌感染高达100

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael S Gilmore其他文献

Michael S Gilmore的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael S Gilmore', 18)}}的其他基金

The Role of Enterococcus Unique Hypothetical EF1909 in Intrinsic β-lactam Resistance
肠球菌独特的假设 EF1909 在内在 β-内酰胺耐药性中的作用
  • 批准号:
    10569041
  • 财政年份:
    2022
  • 资助金额:
    $ 41万
  • 项目类别:
The Role of Enterococcus Unique Hypothetical EF1909 in Intrinsic β-lactam Resistance
肠球菌独特的假设 EF1909 在内在 β-内酰胺耐药性中的作用
  • 批准号:
    10464409
  • 财政年份:
    2022
  • 资助金额:
    $ 41万
  • 项目类别:
Determinants of Ocular Surface Biogeography
眼表生物地理学的决定因素
  • 批准号:
    10396467
  • 财政年份:
    2020
  • 资助金额:
    $ 41万
  • 项目类别:
Determinants of Ocular Surface Biogeography
眼表生物地理学的决定因素
  • 批准号:
    10596574
  • 财政年份:
    2020
  • 资助金额:
    $ 41万
  • 项目类别:
New understanding of LTA as a determinant of daptomycin susceptibility in VRE E. faecium
对 LTA 作为 VRE 屎肠球菌达托霉素敏感性决定因素的新认识
  • 批准号:
    9926227
  • 财政年份:
    2019
  • 资助金额:
    $ 41万
  • 项目类别:
New understanding of LTA as a determinant of daptomycin susceptibility in VRE E. faecium
对 LTA 作为 VRE 屎肠球菌达托霉素敏感性决定因素的新认识
  • 批准号:
    9810471
  • 财政年份:
    2019
  • 资助金额:
    $ 41万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    9151285
  • 财政年份:
    2016
  • 资助金额:
    $ 41万
  • 项目类别:
Subproject 3 New Approaches to Treatment and Prevention of Antibiotic Resistant Infection
子项目3 治疗和预防抗生素耐药感染的新方法
  • 批准号:
    9151288
  • 财政年份:
    2016
  • 资助金额:
    $ 41万
  • 项目类别:
Molecular Basis for Ocular Surface Tropism in Conjunctivitis
结膜炎眼表向性的分子基础
  • 批准号:
    9264533
  • 财政年份:
    2014
  • 资助金额:
    $ 41万
  • 项目类别:
Molecular Basis for Ocular Surface Tropism in Conjunctivitis
结膜炎眼表向性的分子基础
  • 批准号:
    8670576
  • 财政年份:
    2014
  • 资助金额:
    $ 41万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 41万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 41万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 41万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 41万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 41万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 41万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 41万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 41万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 41万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了